ReviewInternal medicine (Tokyo, Japan)2018
An Overview of Kidney Disease Following Hematopoietic Cell Transplantation.
Review in Internal medicine (Tokyo, Japan), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Kidney biopsy analysis of 14 cases of renal disease after unrelated cord blood transplantation.BMC nephrology · 2026Article
- Comparison of the performance of different formulae to assess eGFR in children after allogenic hematopoietic stem cell transplantation.Central European journal of urology · 2025Article
- Chronic Kidney Disease in Pediatric Recipients of Hematopoietic Stem Cell Transplantation in a 5-Year Observation-A Single Center Experience.International journal of pediatrics · 2025Article
- Assessment of Risk Factors for Acute Kidney Injury with Machine Learning Tools in Children Undergoing Hematopoietic Stem Cell Transplantation.Journal of clinical medicine · 2024Article
- Clinical Features of Acute Kidney Injury in the Early Post-Transplantation Period Following Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation.Transplantation and cellular therapy · 2023Article
- Double Malignancy and Double Transplant-A Bumpy Road to Success.Medicina (Kaunas, Lithuania) · 2023Article
- The Onco-Nephrology Field: The Role of Personalized Chemotherapy to Prevent Kidney Damage.Cancers · 2023Review
- Acute kidney injury and chronic kidney disease in umbilical cord blood transplant recipients.Frontiers in oncology · 2023Article
- Acute kidney injury within 100 days post allogeneic hematopoietic cell transplantation is associated with increased risk of post-transplant complications and poor transplant outcomes.Bone marrow transplantation · 2022Article
- The Impact of Allogeneic Hematopoietic Stem Cell Transplantation on Kidney Function in Children-A Single Center Experience.Journal of clinical medicine · 2021Article
- Nephrotic syndrome in syngeneic hematopoietic stem cell transplantation recipients: A case report.World journal of clinical cases · 2021Article
- Risks of Muscle Atrophy in Patients with Malignant Lymphoma after Autologous Stem Cell Transplantation.Physical therapy research · 2021Article
- Reactivation of resolved hepatitis B virus infection combined with nephrotic syndrome in a patient after allogeneic haematopoietic stem cell transplantation.BMC infectious diseases · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hematopoietic stem cell transplantation (SCT) recipients are exposed to a large amount of anti-cancer drugs, immunosuppressors, and irradiation during the peri-SCT period. Thus, they have to overcome serious adverse events related to unavoidable but toxic procedures, including organ disorders. In particular, acute kidney injury (AKI) is one of the most critical complications, because it influences the mortality of patients. A few patients who survive AKI may develop nephrotic syndrome, and precedent AKI is also closely associated with chronic and progressive loss of the renal function in post-SCT patients. These kidney diseases place a heavy burden on SCT patients, both medically and economically. Therefore, hematologists who evaluate SCT should be fully aware of the development of these kidney diseases after SCT. We herein review the common course of kidney disease development following allogeneic SCT to provide healthcare professionals with practical information on renal disease in SCT patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.